Patents by Inventor Jonathan Allan Meulbroek

Jonathan Allan Meulbroek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Water-miscible esters of mono--and diglycerides having antibacterial activity and their use in inhibiting infection
    Patent number: 5908862
    Abstract: A process of treating a bacterial infection in a subject in need of such treatment including the step of administering to the subject an effective bactericidal amount of diacetyltartaric acid esters of mono- and diglycerides is provided. Pharmaceutical compositions containing diacetyltartaric acid esters of mono- and diglycerides as an active bactericidal agent are also provided.
    Type: Grant
    Filed: July 31, 1996
    Date of Patent: June 1, 1999
    Assignee: Abbot Laboratories
    Inventors: Theresa Siu-Ling Wai Lee, Joseph Schaller, Steven N. Anderson, Terry Bruce Mazer, Milo Duane Hilty, Melinda Guzman-Harty, Jonathan Allan Meulbroek, Patricia Joan Ewing, Jin-Zhou Liu
  • Oral rehydration solution containing indigestible oligosaccharides
    Patent number: 5733579
    Abstract: An oral rehydration solution contains indigestible oligosaccharides. Diarrhea related dehydration requires fluid and electrolyte replacement. The primary etiology of antibiotic-associated diarrhea (also known as pseudomembranous colitis) has been recognized as Clostridium difficile. It is believed that the indigenous microflora of a healthy individual suppresses the normally present C. difficile. However, when the indigenous microflora are disrupted (e.g., during antibiotic treatment) overgrowth of C. difficile may occur causing diarrhea and colitis. Treatment of diarrhea related to C. difficile with rehydration therapy and antibiotics has proven effective, but many times relapse occurs. It has been suggested that normalization of the microflora will inhibit C. difficile relapse. Indigestible oligosaccharides have been shown to inhibit C. difficile infection.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: March 31, 1998
    Assignee: Abbott Laboratories
    Inventors: Bryan Warren Wolf, Keith Allen Garleb, Sheila Martinson Campbell, Jonathan Allan Meulbroek, Keith Brian Wheeler, Joseph Edward Walton
  • Inhibition of C. difficile infections by indigestible oligosaccharides
    Patent number: 5688777
    Abstract: The primary etiology of antibiotic-associated diarrhea (which may lead to pseudomembranous colitis) has been recognized as Clostridium difficile. It is believed that the indigenous microflora of a healthy individual suppresses the normally present C. difficile. However, when the indigenous microflora are disrupted (e.g., during antibiotic treatment) overgrowth of C. difficile may occur causing diarrhea and colitis. Treatment of C. difficile with antibiotics has proven effective, but many times relapse occurs. The present invention involves a non-antibiotic approach to the treatment and/or prevention of C. difficile--associated diseases. A therapeutically effective amount of an indigestible oligosaccharide inhibits the infection of mammals by C. difficile when administered enterally.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: November 18, 1997
    Assignee: Abbott Laboratories
    Inventors: Keith Allen Garleb, Bryan Warren Wolf, Jonathan Allan Meulbroek, Keith Brian Wheeler